In:
International Journal of Cancer, Wiley, Vol. 148, No. 7 ( 2021-04), p. 1685-1694
Kurzfassung:
What's new? While different novel treatment options have been approved for the vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) refractory setting in metastatic renal cell carcinoma (mRCC), choosing the optimal second‐line therapy regimen remains a biologic and therapeutic challenge. The MARC‐2 phase IV trial aimed to investigate clinical outcomes in mRCC patients treated with everolimus after failure of one VEGFR‐TKI therapy and to identify subgroups benefiting most. According to the data, everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy, with the greatest benefit seen in patients ≥65 years or with BMI 〉 25 kg/m 2 .
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2021
ZDB Id:
218257-9
ZDB Id:
1474822-8
